Zhu Jie, Liang Qingchun, He Siyi, Wang Chen, Lin Xiafei, Wu Duozhi, Lin Guanwen, Wang Zhihua
Department of Anesthesiology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Department of Anesthesiology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.
Front Pharmacol. 2023 Jan 12;13:1109400. doi: 10.3389/fphar.2022.1109400. eCollection 2022.
Employing network pharmacology in neurodegenerative diseases (NDs) has been extensively studied recently. However, no comprehensive study has conducted on this subject employing bibliometrics so far. The purpose of this study was to find out the developmental trends and hotspots, and to predict potential research directions in this filed. Relevant research were collected from the Web of Science Core Collection Bibliometrics and visual analysis were executed using CiteSpace, VOSviewer, Histcite and R-bibliometrix. A total of 420 English articles on network pharmacology in NDs published in 2008-2022 were obtained from the WOSCC database. From 2008 to 2022, annual publications showed a steady growing trend, especially in 2014-2022. China, Beijing Univ Chinese Med, Frontiers in Pharmacology, and Geerts H are the most prolific country, institution, journal, and author, respectively. China, Nucleic Acids Research, and Hopkins AL are the most highly cited country, journal, and author, respectively. Moreover, network pharmacology and Alzheimer's disease are the focal areas of current researches according to analysis of co-cited references and keywords. Finally, in the detection of burst keywords, systems pharmacology and database are new approaches to disease and drug research, while traditional Chinese medicine (TCM) and Alzheimer's disease are hot research directions. The above keywords are speculated to be the research frontiers. Network pharmacology and Alzheimers' disease are the main topics of researches on network pharmacology in NDs. Network pharmacology and the TCM treatment of Alzheimer's disease have been the recent research hotspots. To sum up, the potential for exploring TCM treatment of AD with network pharmacology is huge.
近年来,网络药理学在神经退行性疾病(NDs)中的应用得到了广泛研究。然而,迄今为止,尚未有关于该主题的文献计量学综合研究。本研究的目的是找出该领域的发展趋势和热点,并预测潜在的研究方向。从科学网核心合集收集相关研究,并使用CiteSpace、VOSviewer、Histcite和R-bibliometrix进行文献计量学和可视化分析。从WOSCC数据库中获得了2008年至2022年发表的420篇关于网络药理学在神经退行性疾病中的英文文章。2008年至2022年,年度出版物呈稳步增长趋势,尤其是在2014年至2022年期间。中国、北京中医药大学、《药理学前沿》和Geerts H分别是发文量最多的国家、机构、期刊和作者。中国、《核酸研究》和Hopkins AL分别是被引频次最高的国家、期刊和作者。此外,根据共被引参考文献和关键词分析,网络药理学和阿尔茨海默病是当前研究的重点领域。最后,在突发关键词检测中,系统药理学和数据库是疾病和药物研究的新方法,而中药(TCM)和阿尔茨海默病是热门研究方向。上述关键词被推测为研究前沿。网络药理学和阿尔茨海默病是神经退行性疾病网络药理学研究的主要主题。网络药理学和中药治疗阿尔茨海默病一直是近期的研究热点。综上所述,利用网络药理学探索中药治疗阿尔茨海默病的潜力巨大。